Biotechnology Acquisitions in Florida

Zephyr AI has acquired Aster Insights, a provider of scientific and clinical intelligence for oncology discovery, making Aster a wholly owned subsidiary to deepen Zephyr's real-world evidence and oncology data capabilities. Concurrently, Zephyr appointed Dr. Allen Chao, founder of Watson Pharmaceuticals, as CEO to lead the combined company's expansion of AI-driven precision medicine and clinical trial optimization.

Fifty 1 Labs, Inc. (OTC: FITY) has acquired Genetic Networks LLC in a transaction announced March 2025; several press releases indicate the deal was structured as a stock consideration (one report cites a $10 million stock deal). 4Cable TV International, Inc. (OTC: CATV) facilitated the transaction as part of its reverse-merger preparations and announced a related dividend for CATV shareholders; Fifty 1 Labs said the acquisition positions it to pursue expanded biotech capabilities and potential multi-million-dollar DoD contracts.

INVO Bioscience has completed a reverse-triangular merger to acquire 100% of NAYA Biosciences, and the combined company will operate as NAYA Biosciences (NASDAQ: NAYA). The combined business will continue INVO's revenue-generating fertility operations while adding NAYA's clinical-stage oncology and autoimmune therapeutics pipeline and updating management and board composition.

Branded Legacy, Inc. (OTC.PK: BLEG), a Melbourne, Florida–based pharmaceutical biotechnology company, has completed the acquisition of All In Extracts LLC, a Tampa, Florida–based medicinal ethnobotany and botanical extracts manufacturer. The deal adds proprietary delivery systems, lab and cultivation capacity (including 800 sq ft of lab space and 16 acres of grow space) to Branded Legacy’s subsidiaries and supports product and capability expansion into supplements and related health-and-wellness markets.

Cyclo Therapeutics completed an all-stock merger with Applied Molecular Transport (AMT), with AMT shareholders receiving 0.1331 shares of Cyclo Therapeutics for each AMT share (approximately 5,822,720 Cyclo shares, or ~18% of the combined company). The combined, Nasdaq-listed company will operate as Cyclo Therapeutics, focus on advancing the Phase 3 TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C1, be led by Cyclo's existing management and headquartered in Gainesville, Florida.

Branded Legacy, Inc. (OTC: BLEG) completed the acquisition of MariJ Pharmaceuticals, Inc., a Clearwater, Florida-based certified-organic CBD extraction and production company, on December 4, 2023. The deal transfers MariJ's mobile CO2 extraction units, licensed vehicles, production lab, IP (including a patent), organic certifications, customer and operational databases, and licenses to Branded Legacy in exchange for preferred series stock and cash.

Lobe Sciences Ltd. signed an amendment to its share purchase agreement to acquire a 100% interest in Altemia & Company, LLC, including assets, know‑how, IP and commercial inventory related to Altemia, a medical food for sickle cell disease. The amended terms provide for the return and milestone-based reissuance of 76,000,000 Lobe common shares to the Altemia selling members upon achievement of specified development, delivery, commercial sale and tech-transfer milestones.

Clairvest Group Inc., together with its Clairvest Equity Partners VI co-investment pool, made a US$25 million equity investment in Boca Biolistics, partnering with management (founders Valentin Adia and Michael Morris) who rolled a meaningful portion of their equity. Boca Biolistics is a clinical research organization and biobanking/biomaterials company that procures, stores and sells human biospecimens and also provides in-house analytical laboratory services; the capital will support the company’s next phase of growth and capability expansion.

Syncona Limited will acquire Applied Genetic Technologies Corporation (AGTC) via a tender offer, paying $0.34 per share in cash upfront (approximately $23.5 million) with contingent value rights (CVRs) that could provide up to an additional $0.73 per share (up to $50.0 million) for total potential consideration of up to $1.07 per share. The transaction, unanimously approved by AGTC’s board, will take AGTC private and is intended to advance AGTC's retinal gene therapy programs amid funding challenges for the public company.

Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.

Arcline Investment Management has acquired a majority interest in Akron Biotechnology LLC, a supplier of cGMP-compliant materials and services for cell and gene therapy manufacturers. Akron will remain led by founder and CEO Dr. Claudia Zylberberg, and Arcline plans to expand Akron's manufacturing capacity and pursue complementary acquisitions to build a platform in regenerative medicine.